// App-Quantinova.ai

: Comparison of Cure Rates between Gemtuzumab Ozogamicin Plus Standard of Care Chemotherapy Vs Standard of Care Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia

Researchers

Presenter

  • Bogdan Muresan

Principal Investigators

  • Carla M. Mamolo

  • Joseph C Cappelleri

  • Ruth Mokgokong

  • Athina Palaka

  • Robert K. Hills

  • Nicholas Latimer

  • Bart Heeg

Medical Centers

  • Ingress Health, Rotterdam, Netherlands

  • Pfizer, Groton, CT

  • Pfizer Inc., Walton Oaks, United Kingdom

  • Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University, Cardiff, United Kingdom

  • University of Sheffield, Sheffield, United Kingdom

Locations

  • Netherlands

  • United States

  • United Kingdom

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Gemtuzumab ozogamicin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved